封面
市场调查报告书
商品编码
1703358

风湿病治疗市场-全球产业规模、份额、趋势、机会和预测(按适应症、配销通路、地区和竞争细分,2020-2030 年)

Rheumatology Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Indication, By Distribution Channel, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球风湿病治疗市场价值为 261.1 亿美元,预计到 2030 年将达到 370.5 亿美元,预测期内年复合成长率(CAGR) 为 5.98%。

市场概览
预测期 2026-2030
2024年市场规模 261.1亿美元
2030年市场规模 370.5亿美元
2025-2030 年复合年增长率 5.98%
成长最快的领域 网路药局
最大的市场 北美洲

风湿病治疗学是医学科学的一个专门领域,专注于风湿病的诊断和治疗,风湿病主要影响肌肉骨骼系统 - 关节、肌肉、骨骼和结缔组织。这些情况通常表现为关节疼痛、僵硬、发炎和活动受限。治疗方法旨在缓解症状、控制病情进展并提高患者的生活品质。

类风湿性关节炎、骨关节炎和狼疮等疾病的发生率和盛行率不断上升,推动了对风湿病治疗的需求。主要促成因素包括全球人口老化和生活方式的改变。生物疗法(如 TNF 抑制剂、白血球介素抑制剂和 JAK 抑制剂)继续占据市场主导地位,这得益于持续的研发推出更有效的治疗方案。

关键市场驱动因素

风湿病患病率上升

主要市场挑战

治疗费用高昂

儘管生物相似药有望降低治疗成本,但由于市场犹豫以及医疗保健提供者和患者的认识有限,更广泛的采用仍然是一个障碍。

主要市场趋势

转向以病人为中心的护理

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第四章:顾客之声

第五章:全球风湿病治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依适应症(僵直性脊椎炎、痛风、骨关节炎、干癣关节炎、类风湿性关节炎)
    • 按配销通路(医院药房、零售药房、网路药房)
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第六章:亚太风湿病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 澳洲
    • 日本
    • 韩国

第七章:欧洲风湿病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 8 章:北美风湿病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 美国
    • 墨西哥
    • 加拿大

第九章:南美洲风湿病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲风湿病治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章:全球风湿病治疗市场:SWOT 分析

第 14 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 15 章: 大环境分析

第 16 章:竞争格局

  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Novartis AG
  • Janssen Pharmaceuticals, Inc.
  • Sanofi SA
  • Johnson & Johnson Private Limited
  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd

第 17 章:策略建议

第18章调查会社について・免责事项

简介目录
Product Code: 16870

Global Rheumatology therapeutics market was valued at USD 26.11 billion in 2024 and is projected to reach USD 37.05 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.98% during the forecast period.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 26.11 Billion
Market Size 2030USD 37.05 Billion
CAGR 2025-20305.98%
Fastest Growing SegmentOnline Pharmacies
Largest MarketNorth America

Rheumatology therapeutics is a specialized area of medical science focused on the diagnosis and treatment of rheumatic diseases, which primarily affect the musculoskeletal system-joints, muscles, bones, and connective tissues. These conditions commonly manifest as joint pain, stiffness, inflammation, and limited mobility. The therapeutic approach aims to alleviate symptoms, manage disease progression, and enhance the quality of life for patients.

The increasing incidence and prevalence of conditions such as rheumatoid arthritis, osteoarthritis, and lupus are fueling demand for rheumatology therapeutics. Key contributing factors include an aging global population and lifestyle-related changes. Biologic therapies-such as TNF inhibitors, interleukin inhibitors, and JAK inhibitors-continue to dominate the market, driven by ongoing R&D introducing more effective treatment options.

Key Market Drivers

Rising Prevalence of Rheumatic Diseases

The growing global burden of rheumatic conditions-including osteoarthritis, rheumatoid arthritis, and gout-can be attributed to several interrelated factors. Aging demographics are a major contributor, with conditions like osteoarthritis increasing proportionally with age. In 2019, approximately 528 million people globally were affected by osteoarthritis, representing a 113% rise since 1990. Nearly 73% of these individuals were over the age of 55.

Obesity is another key risk factor. In 2022, one in eight people globally were classified as obese, with adult obesity rates more than doubling since 1990. Additionally, sedentary lifestyles-prevalent in modern societies-have been linked to a surge in musculoskeletal and joint disorders. As of 2022, nearly one-third of adults worldwide were insufficiently physically active.

Genetic predisposition also plays a significant role. For example, heritability in rheumatoid arthritis is estimated at around 60%, with strong associations to specific genetic markers such as HLA. Environmental factors like air pollution have also been linked to the development and exacerbation of these conditions.

Improvements in diagnostic tools and heightened awareness among healthcare professionals have led to earlier and more accurate diagnoses. In the U.S., 21.2% of adults-approximately 53.2 million people-were diagnosed with arthritis between 2019 and 2021. Many of these diseases are chronic, further increasing prevalence due to long-term disease management.

Gender disparities are also notable; rheumatoid arthritis affects women two to three times more frequently than men. Additionally, rheumatic conditions often coexist with comorbidities such as cardiovascular disease and diabetes, compounding the healthcare burden. Regional differences in diet, healthcare access, and lifestyle also influence prevalence rates. Collectively, these factors underscore the growing need for effective rheumatology therapeutics and continued innovation in treatment approaches.

Key Market Challenges

High Cost of Treatment

One of the primary challenges in the rheumatology therapeutics market is the high cost of treatment, particularly for biologic drugs. Despite insurance coverage, patients frequently incur substantial out-of-pocket expenses, leading to treatment non-adherence and poorer health outcomes.

These high costs can exacerbate disparities in care access, particularly among lower-income populations, resulting in delayed diagnoses and suboptimal treatment. Publicly funded healthcare systems also face budgetary constraints that limit the availability and quality of rheumatologic treatments.

Moreover, the cost burden extends to health insurers and employers, often resulting in increased insurance premiums. Concerns over affordability have prompted discussions among policymakers and advocacy groups regarding drug pricing reforms and greater transparency in healthcare costs.

Rheumatic diseases can significantly impair physical functioning, resulting in decreased work productivity and higher disability rates. The combined effect of disease burden and high treatment costs poses economic challenges for individuals and healthcare systems alike.

Although biosimilars hold promise for reducing treatment costs, broader adoption remains a hurdle due to market hesitancy and limited awareness among healthcare providers and patients.

Key Market Trends

Shift Toward Patient-Centric Care

The market is witnessing a paradigm shift toward patient-centered care, with a strong emphasis on shared decision-making. Healthcare providers are involving patients in the development of personalized treatment plans, taking into account disease severity, lifestyle, comorbidities, and individual preferences.

Education and empowerment are integral components of this approach. By equipping patients with a better understanding of their condition and available treatment options, providers can foster more active patient participation in disease management.

Efforts are also being made to address access and affordability challenges. Healthcare institutions are working to minimize financial barriers and ensure equitable access to necessary treatments.

Patient-centric models promote continuous monitoring of disease activity, encouraging patients to communicate regularly with their healthcare teams. Pain management, as a core concern, is customized based on individual needs.

Key Market Players

  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Amgen Inc.
  • Novartis AG
  • Janssen Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson Private Limited
  • F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Rheumatology Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Rheumatology Therapeutics Market, By Indication:

  • Ankylosing Spondylitis
  • Gout
  • Osteoarthritis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis

Rheumatology Therapeutics Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Rheumatology Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Australia
    • Japan
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Rheumatology Therapeutics Market.

Available Customizations:

Global Rheumatology Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Rheumatology Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Ankylosing Spondylitis, Gout, Osteoarthritis, Psoriatic Arthritis, Rheumatoid Arthritis)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Rheumatology Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Rheumatology Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. India Rheumatology Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Australia Rheumatology Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Distribution Channel
    • 6.3.4. Japan Rheumatology Therapeutics Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Indication
        • 6.3.4.2.2. By Distribution Channel
    • 6.3.5. South Korea Rheumatology Therapeutics Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Indication
        • 6.3.5.2.2. By Distribution Channel

7. Europe Rheumatology Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Rheumatology Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. Germany Rheumatology Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. Spain Rheumatology Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Rheumatology Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. United Kingdom Rheumatology Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Distribution Channel

8. North America Rheumatology Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Rheumatology Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. Mexico Rheumatology Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Canada Rheumatology Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Distribution Channel

9. South America Rheumatology Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Rheumatology Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. Argentina Rheumatology Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. Colombia Rheumatology Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Distribution Channel

10. Middle East and Africa Rheumatology Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Rheumatology Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Saudi Arabia Rheumatology Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. UAE Rheumatology Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Rheumatology Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. AbbVie Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Bristol-Myers Squibb Company
  • 16.3. Pfizer Inc.
  • 16.4. Merck & Co., Inc.
  • 16.5. Amgen Inc.
  • 16.6. Novartis AG
  • 16.7. Janssen Pharmaceuticals, Inc.
  • 16.8. Sanofi SA
  • 16.9. Johnson & Johnson Private Limited
  • 16.10. Takeda Pharmaceutical Company Limited
  • 16.11. F. Hoffmann-La Roche Ltd

17. Strategic Recommendations

18. About Us & Disclaimer